Published on 10 May 2024 on GuruFocus.com via Yahoo Finance
ADMA Biologics Inc (ADMA) Surpasses Analyst Revenue and Earnings Forecasts in Q1 2024
Revenue: Reported $81.9 million, a 44% increase year-over-year, surpassing estimates of $77.28 million.Net Income: Achieved $17.8 million, a significant improvement from a net loss of $6.8 million year-over-year, exceeding estimates of $12.43 million.Adjusted EBITDA: Reached $26.4 million, marking a 970% increase from the previous year.Gross Margin: Improved to 48% in Q1 2024 from 29% in Q1 2023.Future Revenue Guidance: Increased for FY 2024 to over $355 million and for FY 2025 to over $410 million.Future Net Income Guidance: Raised to more than $85 million for FY 2024 and over $135 million for FY 2025.
Warning! GuruFocus has detected 5 Warning Sign with ADMA.